BI 34021Alternative Names: BI 34021 FU2; BI34021
Latest Information Update: 16 Oct 2014
At a glance
- Originator Boehringer Ingelheim
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 01 Oct 2014 Discontinued - Phase-I for Undefined indication (In volunteers) in Germany (PO, tablet and PO, solution)
- 23 Jun 2008 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT02259842)
- 28 Mar 2008 Phase-I clinical trials in Undefined indication (In volunteers) in Germany (PO, tablet and PO, solution)